b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">31642795</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>05</Month>\n            <Day>15</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Electronic">1996-3181</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>18</Volume>\n                    <Issue>9</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                    </PubDate>\n                </JournalIssue>\n                <Title>CNS &amp; neurological disorders drug targets</Title>\n                <ISOAbbreviation>CNS Neurol Disord Drug Targets</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Combined Ischemic Preconditioning and Resveratrol Improved Bloodbrain Barrier Breakdown <i>via</i> Hippo/YAP/TAZ Signaling Pathway.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>713-722</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.2174/1871527318666191021144126</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND">Transient Ischemia/Reperfusion (I/R) is the main reason for brain injury and results in disruption of the Blood-Brain Barrier (BBB). It had been reported that BBB injury is one of the main risk factors for early death in patients with cerebral ischemia. Numerous investigations focus on the study of BBB injury which have been carried out.</AbstractText>\n                <AbstractText Label="OBJECTIVE">The objective of this study was to investigate the treatment function of the activation of the Hippo/Yes-Associated Protein (YAP) signaling pathway by combined Ischemic Preconditioning (IPC) and resveratrol (RES) before brain Ischemia/Reperfusion (BI/R) improves Blood-Brain Barrier (BBB) disruption in rats.</AbstractText>\n                <AbstractText Label="METHODS">Sprague-Dawley (SD) rats were pretreated with 20 mg/kg RES and IPC and then subjected to 2 h of ischemia and 22 h of reperfusion. The cerebral tissues were collected; the cerebral infarct volume was determined; the Evans Blue (EB) level, the brain Water Content (BWC), and apoptosis were assessed; and the expressions of YAP and TAZ were investigated in cerebral tissues.</AbstractText>\n                <AbstractText Label="RESULTS">Both IPC and RES preconditioning reduced the cerebral infarct size, improved BBB permeability, lessened apoptosis, and upregulated expressions of YAP and transcriptional co-activator with PDZ-binding motif (TAZ) compared to the Ischemia/Reperfusion (I/R) group, while combined IPC and RES significantly enhanced this action.</AbstractText>\n                <AbstractText Label="CONCLUSION">combined ischemic preconditioning and resveratrol improved blood-brain barrier breakdown via Hippo/YAP/TAZ signaling pathway.</AbstractText>\n                <CopyrightInformation>Copyright\xc2\xa9 Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Hong</LastName>\n                    <ForeName>Ganji</ForeName>\n                    <Initials>G</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, The First Affiliated Hospital of Xiamen University, Xiamen, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Yan</LastName>\n                    <ForeName>Ying</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Rehabilitation Medicine, Zhejiang Chinese Medical University, The Third Clinical Medicine, Hangzhou, Zhejiang, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhong</LastName>\n                    <ForeName>Yali</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>College of Life Science and Engineering, Southwest University of Science and Technology, Mianyang, Sichuan, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Chen</LastName>\n                    <ForeName>Jianer</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Rehabilitation Medicine, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tong</LastName>\n                    <ForeName>Fei</ForeName>\n                    <Initials>F</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>School of Pharmaceutical Science, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou, 510515, China.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pathology and Pathophysiology, Provincial Key Discipline of Pharmacology, Jiaxing University Medical College, Jiaxing, China.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Endocrinology and Diabetes, The First Affiliated Hospital, Xiamen University, Xiamen, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ma</LastName>\n                    <ForeName>Qilin</ForeName>\n                    <Initials>Q</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Neurology, The First Affiliated Hospital of Xiamen University, Xiamen, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United Arab Emirates</Country>\n            <MedlineTA>CNS Neurol Disord Drug Targets</MedlineTA>\n            <NlmUniqueID>101269155</NlmUniqueID>\n            <ISSNLinking>1871-5273</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Blood-Brain Barrier (BBB)</Keyword>\n            <Keyword MajorTopicYN="Y">Brain Ischemia/Reperfusion Injury (BI/RI)</Keyword>\n            <Keyword MajorTopicYN="Y">Brain Water Content (BWC)</Keyword>\n            <Keyword MajorTopicYN="Y">Hippo/YAP/TAZ</Keyword>\n            <Keyword MajorTopicYN="Y">Ischemic Preconditioning (IPC)</Keyword>\n            <Keyword MajorTopicYN="Y">Resveratrol (RES).</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>04</Month>\n                <Day>12</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2019</Year>\n                <Month>09</Month>\n                <Day>12</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>09</Month>\n                <Day>13</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>10</Month>\n                <Day>24</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>10</Month>\n                <Day>24</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>10</Month>\n                <Day>24</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31642795</ArticleId>\n            <ArticleId IdType="pii">CNSNDDT-EPUB-101721</ArticleId>\n            <ArticleId IdType="doi">10.2174/1871527318666191021144126</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'